This Tuesday, December 3, the presentation of the second part of the Health Reputation Monitor (MRS) 2024 took place, dedicated to the pharmaceutical companies with the best reputation.

MRS has carried out an analysis of 25 therapeutic areas in which we observe which are the companies with the best reputation and the most innovative, in addition to the general ranking, which in this 10th edition is led by Pfizer (1st), Novartis (2nd) and AstraZeneca ( 3rd), Johnson & Johnson (4th), Roche (5th), Bayer (6th), Sanofi (7th), Lilly (8th), GlaxoSmithKline – GSK (9th) and Abadía (10th). 

In this 10th edition, 11 evaluations and 43,910 surveys have been carried out among healthcare professionals (doctors, nurses, patient associations, health informants, hospital managers, nursing managers, members of the public health administration, hospital pharmacy managers and directors of pharmaceutical companies). Along with these evaluations, an analysis has been carried out in the digital field (Merco Digital), with more than 124,825 mentions and publications analyzed. At the same time, to analyze attractiveness as employers, 37,382 surveys were conducted among different audiences. And an evaluation of reputational merits has also been carried out on 38 companies.

See Pharmaceutical companies ranking

See other MRS rankings